Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston Texas talked to us about the recent data he presented at the 58th Annual ASH Meeting & Exposition showing the long term efficacy of jakafi (ruxolitinib) in patients with myelofibrosis.
Verstovsek S, Gupta V, Gotlib J, et al. A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Presented at the 58th Annual ASH Meeting and Exposition; San Diego, CA; December 3-6, 2016. Abstract 3110.